Pharmacokinetics of metoprolol during pregnancy and lactation

Rachel J. Ryu, Sara Eyal, Thomas R. Easterling, Steve N. Caritis, Raman Venkataraman, Gary Hankins, Erik Rytting, Kenneth Thummel, Edward J. Kelly, Linda Risler, Brian Phillips, Matthew T. Honaker, Danny D. Shen, Mary F. Hebert

    Research output: Contribution to journalArticle

    18 Scopus citations


    The objective of this study was to evaluate the steady-state pharmacokinetics of metoprolol during pregnancy and lactation. Serial plasma, urine, and breast milk concentrations of metoprolol and its metabolite, α-hydroxymetoprolol, were measured over 1 dosing interval in women treated with metoprolol (25-750 mg/day) during early pregnancy (n = 4), mid-pregnancy (n = 14), and late pregnancy (n = 15), as well as postpartum (n = 9) with (n = 4) and without (n = 5) lactation. Subjects were genotyped for CYP2D6 loss-of-function allelic variants. Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P

    Original languageEnglish (US)
    Pages (from-to)581-589
    Number of pages9
    JournalJournal of Clinical Pharmacology
    Issue number5
    StatePublished - May 1 2016



    • breast milk
    • CYP2D6
    • hypertension
    • metoprolol
    • pharmacokinetics
    • pregnancy

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology

    Cite this

    Ryu, R. J., Eyal, S., Easterling, T. R., Caritis, S. N., Venkataraman, R., Hankins, G., Rytting, E., Thummel, K., Kelly, E. J., Risler, L., Phillips, B., Honaker, M. T., Shen, D. D., & Hebert, M. F. (2016). Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology, 56(5), 581-589.